200 related articles for article (PubMed ID: 33653677)
1. Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation.
Nocera L; Collà Ruvolo C; Stolzenbach LF; Wenzel M; Tian Z; Larcher A; Capitanio U; Mirone V; Tilki D; Chun FKH; Kapoor A; Shariat SF; Saad F; Montorsi F; Briganti A; Karakiewicz PI
Eur Urol Focus; 2022 Jan; 8(1):182-190. PubMed ID: 33653677
[TBL] [Abstract][Full Text] [Related]
2. Cancer-specific Mortality in T1a Renal Cell Carcinoma Treated with Local Tumor Destruction Versus Partial Nephrectomy.
Sorce G; Hoeh B; Hohenhorst L; Panunzio A; Tappero S; Tian Z; Kokorovic A; Larcher A; Capitanio U; Tilki D; Terrone C; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
Eur Urol Focus; 2023 Jan; 9(1):125-132. PubMed ID: 35918270
[TBL] [Abstract][Full Text] [Related]
3. Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma.
Rosiello G; Palumbo C; Knipper S; Pecoraro A; Luzzago S; Tian Z; Larcher A; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Urol Oncol; 2020 May; 38(5):537-544. PubMed ID: 32122729
[TBL] [Abstract][Full Text] [Related]
4. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
[TBL] [Abstract][Full Text] [Related]
5. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.
Beck SD; Patel MI; Snyder ME; Kattan MW; Motzer RJ; Reuter VE; Russo P
Ann Surg Oncol; 2004 Jan; 11(1):71-7. PubMed ID: 14699037
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1-4 cm renal cell carcinomas.
Rosiello G; Pecoraro A; Luzzago S; Deuker M; Stolzenbach LF; Tian Z; Larcher A; Capitanio U; Montorsi F; Shariat SF; Kapoor A; Saad F; Briganti A; Karakiewicz PI
Cancer Causes Control; 2021 Feb; 32(2):119-126. PubMed ID: 33169306
[TBL] [Abstract][Full Text] [Related]
7. A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.
Palumbo C; Mazzone E; Mistretta FA; Knipper S; Perrotte P; Shariat SF; Saad F; Kapoor A; Lattouf JB; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
Clin Genitourin Cancer; 2020 Aug; 18(4):314-321.e1. PubMed ID: 32482565
[TBL] [Abstract][Full Text] [Related]
8. Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy.
Palumbo C; Mistretta FA; Knipper S; Pecoraro A; Tian Z; Shariat SF; Saad F; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
J Natl Compr Canc Netw; 2020 Jan; 18(1):44-51. PubMed ID: 31910387
[TBL] [Abstract][Full Text] [Related]
9. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study.
Capitanio U; Cloutier V; Zini L; Isbarn H; Jeldres C; Shariat SF; Perrotte P; Antebi E; Patard JJ; Montorsi F; Karakiewicz PI
BJU Int; 2009 Jun; 103(11):1496-500. PubMed ID: 19076149
[TBL] [Abstract][Full Text] [Related]
10. The critical impact of tumor size in predicting cancer special survival for T3aM0M0 renal cell carcinoma: A proposal of an alternative T3aN0M0 stage.
Li L; Shi L; Zhang J; Fan Y; Li Q
Cancer Med; 2021 Jan; 10(2):605-614. PubMed ID: 33280246
[TBL] [Abstract][Full Text] [Related]
11. Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?
Capitanio U; Stewart GD; Klatte T; Akdogan B; Roscigno M; Marszalek M; Dell'Oglio P; Zaffuto E; Rodriguez Faba O; Salagierski M; Lingard J; Carini M; Ouzaid I; Mir MC; Montorsi F; Da Pozzo LF; Stief C; Minervini A; Brookman-May SD
Eur Urol Focus; 2018 Dec; 4(6):972-977. PubMed ID: 28753867
[TBL] [Abstract][Full Text] [Related]
12. Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy.
Bandini M; Smith A; Zaffuto E; Pompe RS; Marchioni M; Capitanio U; Chun FK; Kapoor AB; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2018 Jan; 36(1):51-57. PubMed ID: 29022072
[TBL] [Abstract][Full Text] [Related]
13. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study.
Marchioni M; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Primiceri G; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):488-496. PubMed ID: 29229582
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1-pT3a localized renal cell carcinoma in a comprehensive multicenter study of the CORONA project. Can we improve prognostic discrimination for patients with stage pT3a tumors?
Brookman-May SD; May M; Wolff I; Zigeuner R; Hutterer GC; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Truss M; Dalpiaz O; Feciche B; Figenshau RS; Madison K; Sánchez-Chapado M; Santiago Martin Mdel C; Salzano L; Lotrecchiano G; Zastrow S; Wirth M; Sountoulides P; Shariat S; Waidelich R; Stief C; Gunia S; ;
Eur Urol; 2015 May; 67(5):943-51. PubMed ID: 25684695
[TBL] [Abstract][Full Text] [Related]
15. Does Reduced Renal Function Predispose to Cancer-specific Mortality from Renal Cell Carcinoma?
Palacios DA; Zabor EC; Munoz-Lopez C; Roversi G; Mahmood F; Abramczyk E; Kelly M; Wilson B; Abouassaly R; Campbell SC
Eur Urol; 2021 Jun; 79(6):774-780. PubMed ID: 33678521
[TBL] [Abstract][Full Text] [Related]
16. A Population Study to Identify Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Sarcomatoid Renal Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database.
Ji B; Li D; Fu S; Zhang Z; Yang T; Wu Y; Zuo Y; Xu Z; Yu N
Med Sci Monit; 2020 Jun; 26():e921297. PubMed ID: 32516796
[TBL] [Abstract][Full Text] [Related]
17. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
18. Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients.
Piccinelli ML; Barletta F; Tappero S; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Luzzago S; Mistretta FA; Ferro M; Saad F; Shariat SF; Ahyai S; Longo N; Tilki D; Chun FKH; Terrone C; Briganti A; de Cobelli O; Musi G; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):799-806. PubMed ID: 37024421
[TBL] [Abstract][Full Text] [Related]
19. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of tumour size in patients after tumour nephrectomy for localised renal cell carcinoma.
Steiner T; Knels R; Schubert J
Eur Urol; 2004 Sep; 46(3):327-30. PubMed ID: 15306102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
